U.S., July 18 -- ClinicalTrials.gov registry received information related to the study (NCT07070765) titled 'Sodium-glucose Transporter Type 2 Inhibition in Anthracycline-related Cardiotoxicity' on June 26.
Brief Summary: Cardiotoxicity is heart damage that arises from certain drugs, such as those used for cancer treatment and develops in approximately 10% of patients with breast cancer who are treated with anthracyclines. It has been suggested that sodium-glucose transporter-2 (SGLT2) inhibitors may reduce the damage to the heart caused by anthracycline chemotherapy. The investigators wish to determine whether dapagliflozin (SGLT2 inhibitor) taken daily during chemotherapy will reduce the rate of cardiotoxicity.
Study Start Date: Nov. 01...